Clinical Trials
Braintumor Website

There are 17 trials:
Facility: Novartis Investigative Site
NCT Trial Name# of Centers

NCT01708174

  A Phase II Study of Oral LDE225 in Patients With Hedge-Hog (Hh)-Pathway Activated Relapsed Medulloblastoma (MB)
58

NCT00958841

  Study of Pasireotide in Patients With Rare Tumors of Neuroendocrine Origin
35

NCT01324479

  Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
17

NCT02124772

  Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
16

NCT01125800

  A Phase I Dose Finding and Safety Study of Oral LDE225 in Children and a Phase II Portion to Assess Preliminary Efficacy in Recurrent or Refractory MB
11

NCT02381886

  A Study of IDH305 in Patients With Advanced Malignancies That Harbor IDH1R132 Mutations
11

NCT01137682

  Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly
8

NCT01283542

  Evaluate the Efficacy and Safety of Pasireotide LAR on the Treatment of Patients With Clinically Non-Functioning Pituitary Adenoma.
8

NCT01870726

  Safety and Efficacy of INC280 and Buparlisib (BKM120) in Patients With Recurrent Gliobastoma
7

NCT02684058

  Phase II Pediatric Study With Dabrafenib in Combination With Trametinib in Patients With HGG and LGG
7

NCT01106508

  A Dose Finding and Safety Study of Oral LEQ506 in Patients With Advanced Solid Tumors
5

NCT02336451

  A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges
4

NCT02338609

  Long-term Follow-up for Growth and Development of Pediatric Patients From CRAD001M2301
3

NCT03340506

  Dabrafenib and/or Trametinib Rollover Study
2

NCT01208831

  An East Asian Study of LDE225
1

NCT01331239

  Safety and Efficacy of LCI699 in Cushing's Disease Patients.
1

NCT01915303

  Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease
1



Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2018 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557
888-295-4740


Website Design By
World Wide Websites